<i>Anaplastic lymphoma-kinase (ALK)</i>-rearranged non-small cell lung cancer (NSCLC) is prone to developing heterogeneous, only partly known mechanisms of resistance to ALK-tyrosine-kinase-inhibitors (ALK-TKIs). Here, ALK is linked to non-small cell lung carcinoma.